HUB Organoids
HUB Organoids offers services using patient-derived organoid technology for drug discovery, disease modeling, and personalized medicine.
- Acquired Subsidiary
HUB Organoids offers services using patient-derived organoid technology for drug discovery, disease modeling, and personalized medicine.
huborganoids.nlCrawled Oct 23, 2026
Organoid technology enables testing of antibody-drug conjugate efficacy, safety, and tumor antigen expression, as well as discovery of response biomarkers.
HUB Organoids offers patient-derived models to accelerate KRAS-targeted drug discovery, including predictive screens, resistance models, and a diverse biobank.
Selective KRAS inhibitors show limited effectiveness in colorectal cancer, prompting combination strategies targeting EGFR and PI3Kα, though resistance remains a challenge.
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects 25% of the global population, with early-stage disease remaining largely untreated. It progresses from simple steatosis to severe conditions like fibrosis and hepatocellular carcinoma.
Late-stage clinical failure drives most waste in drug research and development, with trials consuming the majority of sunk capital and leaving companies vulnerable to multi-hundred-million-dollar losses when late-stage candidates fail.
HUB Organoids B.V. uses organoid technology to improve preclinical and clinical drug development accuracy and efficiency. Frost & Sullivan recognized HUB with the 2024 Global Technology Innovation Leadership Award for its advancements in this field.
HUB Organoids launched IntegriGut Screen, a screening service using IBD patient-derived organoid monolayers to provide high-quality human data on epithelial barrier function.
News - HUB Organoids
The company applies HUB Organoid Technology globally to benefit patients and encourages employees to innovate and develop their capabilities.
Dear Valued Customer, On Wednesday 11th March the World Health Organization (WHO) declared a pandemic in response to the COVID-19 outbreak. These are very difficult and challenging times for every organization.
The company developed organoids from mouse intestine in 2009 and human intestinal epithelium in 2011. It established the Hubrecht Organoid Technology Foundation in 2013 to commercialize the technology and treated the first cystic fibrosis patient using organoid data in 2015.
HUB Organoids develops patient-derived ‘mini-organs’ from healthy and diseased tissues to predict treatment responses and bridge lab and clinical applications.
MilliporeSigma acquires HUB Organoids Holding B.V., a leader in organoid technology. The move strengthens MilliporeSigma’s portfolio in advanced biological research tools. HUB specializes in developing human organoid models for drug discovery and disease research.
Jan 2025sigmaaldrich.comNews article
MilliporeSigma acquires HUB, a Netherlands-based company specializing in organoid technology, to advance drug development capabilities. The move expands MilliporeSigma’s portfolio in life sciences research tools. Organoids enable more accurate modeling of human tissues for pharmaceutical testing.
Dec 2024BioProcess InternationalNews article
Merck KGaA’s Life Science division acquires **HUB Organoids Holding B.V.**, an internationally recognized leader in organoid development. The move expands Merck’s cell culture portfolio to include 2D and 3D organoid models, a segment poised for rapid growth. Organoids hold promise for accelerating drug development and reducing reliance on animal testing.
Dec 2024HUB Organoids -News article
MilliporeSigma acquires HUB Organoids Holding B.V. to expand its next-generation biology offerings. The move strengthens its portfolio in organoid research, a key area for life sciences. The acquisition aligns with Merck KGaA’s focus on advancing innovative biological tools.
Dec 2024Business WireNews article